uniQure N.V. (QURE)
| Market Cap | 1.75B |
| Revenue (ttm) | 6.05M |
| Net Income (ttm) | -165.75M |
| Shares Out | 44.47M |
| EPS (ttm) | -3.75 |
| PE Ratio | n/a |
| Forward PE | 27.93 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $39.26 |
| Previous Close | $38.58 |
| Change ($) | 0.68 |
| Change (%) | 1.76% |
| Day's Open | 38.26 |
| Day's Range | 37.88 - 39.41 |
| Day's Volume | 301,292 |
| 52-Week Range | 35.35 - 67.74 |
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are advised to ...
Crispr Therapeutics, Editas Medicine and Intellia Therapeutics were ablaze Monday as all three genetics stocks touched highs. Uniqure stock fell on a clinical hold for its gene therapy test.
After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.
Uniqure NV (NASDAQ: QURE) shares are moving sharply to the downside after the gene therapy company announced a setback to its clinical study. What Happened: Lexington, Massachusetts-based uniQ...
Company to hold conference call today at 8:30 a.m. ET Company to hold conference call today at 8:30 a.m. ET
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
~ Sustained FIX Activity at Therapeutic Levels1 with a Mean of 44% of Normal at Two Years After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~
The health care sector as a whole has been a top performer this year, and there is every reason to believe that strong performance will carry through to 2021.
LEXINGTON, Mass and AMSTERDAM, Dec. 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
~ Strong P resence at ASH Featuring Five P resentations , Including Late-Breaking Oral Presentation on HOPE-B Pivotal Trial ~
UniQure NV (NASDAQ: QURE) shares were advancing to four-month highs Thursday in reaction to a positive clinical data readout. What Happened: The Lexington, Massachusetts-based company announce...
Shares of QURE stock bounded higher Thursday after Uniqure reported promising results for its hemophilia B gene therapy. The company says the drug improved clotting protein at 26 weeks.
~ Phase III study in 54 patients met primary endpoint with mean Factor IX activity of 37% of normal at 26 weeks ~
LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medica...
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients w...
uniQure (QURE) delivered earnings and revenue surprises of -171.18% and -98.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
~ Enrolled First Four Patients in Phase I/II Clinical Trial of AMT-130 in Huntington's Disease ~
Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry exp...
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to ge...
UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LEXINGTON, Mass. and AMSTERDAM, Oct. 13, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medica...
Gene therapy - which aims to treat diseases by essentially inserting a gene into a patient’s cells rather than via drugs or surgery - was a hot trend in the biotech space, but investor interes...
LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medic...
~ Independent Data Safety Monitoring Board Recommends Proceeding with Study Enrollment; No Significant Safety Concerns Observed to Prevent Further Dosing ~ ~ Independent Data Safety Monitoring...
LEXINGTON, Mass. and AMSTERDAM, Sept. 03, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe med...
Investors need to pay close attention to uniQure (QURE) stock based on the movements in the options market lately.
Announces Planned Departure of Sander van Deventer and Transition of Robert Gut Who is Expected to Remain on the Board of Directors Announces Planned Departure of Sander van Deventer and Trans...
uniQure (QURE) delivered earnings and revenue surprises of -100.00% and -91.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
~ Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure’s Gene Therapy Candidate for Hemophilia B ~
UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agreement licenses the rights for a promising hemophilia B gene therapy.
Shares of UniQure QURE, -7.13% tumbled 17% in premarket trading on Thursday, the day after it announced that CSL Behring CSL, +0.56% would acquire exclusive commercialization rights to its gen...
Biotech company Uniqure inked a $2 billion licensing deal for its hemophilia B gene therapy late Wednesday. But shares of QURE stock collapsed in response in after-hours trading.
~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~
~ Milestone Marks the First-in-Human AAV Gene Therapy Trial for Huntington’s Disease ~ ~ Milestone Marks the First-in-Human AAV Gene Therapy Trial for Huntington’s Disease ~
~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~
~ Virtual Meeting Only by Live Audio Webcast – No Physical Meeting Location ~
A Relative Strength Rating upgrade for Uniqure N.V. shows improving technical performance.
uniQure N.V. (QURE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Companies that have been able to deliver compelling results have been acquired by big pharma companies (for instance, Spark Therapeutics was acquired by Roche), while others have underperforme...
uniQure (QURE) delivered earnings and revenue surprises of 26.74% and -94.09%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~ ~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~
Provides Update on Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease and Response to COVID-19 Pandemic Provides Update on Phase I/II Clinical Trial of AMT-130 in Huntington’s Disea...
uniQure (QURE) delivered earnings and revenue surprises of -24.36% and 49.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
~ Gen-X Will Work with uniQure During an Exclusivity Period to Identify Novel Promoters for uniQure’s Product Portfolio ~
uniQure (QURE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
About QURE
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an on... [Read more...]
| Industry Biotechnology | IPO Date Jun 20, 2007 |
| CEO Matthew Craig Kapusta | Employees 248 |
| Stock Exchange NASDAQ | Ticker Symbol QURE |
Financial Performance
In 2019, uniQure's revenue was $7.28 million, a decrease of -35.48% compared to the previous year's $11.28 million. Losses were -$124.20 million, 49.1% more than in 2018.
Analyst Forecasts
According to 19 analysts, the average rating for uniQure stock is "Strong Buy." The 12-month stock price forecast is 69.26, which is an increase of 76.41% from the latest price.